Merck osteoporosis drug builds bone density in mid-stage trial

(Reuters) – Hip and spine bone mineral density increased significantly among post-menopausal women on Merck & Co’s experimental new osteoporosis drug who had previously taken a standard older company treatment, the drugmaker said on Saturday. The favorable results were seen in a mid-stage trial of …